Quince Therapeutics Files 2024 10-K
Ticker: QNCX · Form: 10-K · Filed: Mar 24, 2025 · CIK: 1662774
| Field | Detail |
|---|---|
| Company | Quince Therapeutics, Inc. (QNCX) |
| Form Type | 10-K |
| Filed Date | Mar 24, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, biotech, financials
TL;DR
Quince Therapeutics filed its 2024 10-K, detailing financials and operations.
AI Summary
Quince Therapeutics, Inc. filed its 2024 10-K on March 24, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Cortexyme, Inc., is involved in the biological products sector. The filing details financial information and business operations for the period.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Quince Therapeutics' financial health and strategic direction for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a biotechnology company, Quince Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Quince Therapeutics, Inc. (company) — Filer of the 10-K
- Cortexyme, Inc. (company) — Former name of Quince Therapeutics
- 2024-12-31 (date) — Fiscal year end
- 2025-03-24 (date) — Filing date
FAQ
What is Quince Therapeutics, Inc.'s primary business sector?
Quince Therapeutics, Inc. is in the Biological Products sector, specifically SIC code 2836.
When did Quince Therapeutics, Inc. change its name from Cortexyme, Inc.?
The date of the name change from Cortexyme, Inc. to Quince Therapeutics, Inc. was January 4, 2016.
What is the business address of Quince Therapeutics, Inc.?
The business address is 611 Gateway Blvd., Suite 273, South San Francisco, CA 94080.
What is the SEC file number for Quince Therapeutics, Inc.?
The SEC file number is 001-38890.
What period does this 10-K filing cover?
This 10-K filing covers the fiscal year ending December 31, 2024.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 24, 2025 regarding Quince Therapeutics, Inc. (QNCX).